Skip to Content
Merck
  • Discovery of potent thermolysin inhibitors using structure based virtual screening and binding assays.

Discovery of potent thermolysin inhibitors using structure based virtual screening and binding assays.

Journal of medicinal chemistry (2008-12-17)
Mahmud Tareq Hassan Khan, Ole-Martin Fuskevåg, Ingebrigt Sylte
ABSTRACT

In the present work, 22 compounds of the U.S. NCI compound library (size 273K) were identified as putative thermolysin binders by structure based virtual screening with the ICM software (ICM-VLS). In vitro competitive binding assays confirmed that 12 were thermolysin binders. Thermolysin binding modes of the 12 compounds were studied by docking using ICM and Molegro Virtual Docker (MVD). The most potent inhibitor had an IC(50) value of 6.4 x 10(-8) mM (NSC250686, 1 beta-D-arabinofuranosyl-N(4)-lauroylcytosine). The structure of this compound is quite different from the other 11 compounds. Nine out of the 12 compounds contained a similar chemical skeleton (3-nitrobenzamide derivatives) and have IC(50) values ranging from 697.48 to 0.047 mM. The ICM-VLS score and the activity profiles (pIC(50) values) were compared and found to be somewhat linearly correlated (R(2) = 0.78). Kinetic studies showed that, except for NSC285166 (oxyquinoline), the compounds are competitive thermolysin inhibitors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
8-Quinolinol, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99% (perchloric acid titration)
Supelco
8-Quinolinol, PESTANAL®, analytical standard
Sigma-Aldrich
8-Hydroxyquinoline, ACS reagent, 98.5%
Sigma-Aldrich
8-Hydroxyquinoline